Logo for PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics Investor Relations Material

Latest events

Logo for PHAXIAM Therapeutics S.A.

Q4 2023

PHAXIAM Therapeutics
Logo for PHAXIAM Therapeutics

Q4 2023

21 Mar, 2024
Logo for PHAXIAM Therapeutics

Q3 2023

15 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from PHAXIAM Therapeutics S.A.

Access all reports
PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing innovative treatments for drug-resistant bacterial infections. Leveraging phages, which are viruses that specifically target and kill bacteria, the company is developing a portfolio aimed at combating some of the most challenging and resistant bacterial strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is also involved in advancing clinical-stage therapies, including eryaspase, which is being tested in late-stage clinical trials for conditions such as pancreatic cancer and acute lymphoblastic leukemia. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris.